AzTrials
AzTrials

Cervical CancerPhase 2NCT05247619

A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

A Phase 2 study testing Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin in people with Cervical Cancer, run by Zhejiang Cancer Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Efficacy and safety of Tislelizumab combined with Bevacizumab and chemotherapy in patients with persistent, recurrent or metastatic cervical cancer. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Cervical Cancer
What is being tested?
Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
49 participants
Where
1 siteChina
Study dates
30 Jun 2022to Jan 2025
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Voluntary participation and signature of informed consent;
  • Age ≥18;
  • Eastern United States Cancer Collaboration Group (ECOG) score 0-1;
  • Patients with metastatic (IVB), persistent or first recurrent cervical cancer is unsuitable for surgical treatment;
  • Histopathology was defined as: cervical squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, patients included in adenocarcinoma histology will be limited to 20% of the entire study population;
  • Patients must have lesions that can be measured according to RECIST v1.1 criteria;
Show all 20Show fewer
  • The main organs function well and are defined as:
  • Patients received no blood, platelet transfusion or growth factor support treatment within 14 days ≤ the beginning of treatment and was required to:
  • x 109/L ANC ≥1.5
  • Platelet ≥100 x 109/L
  • g/L ≥90
  • AST and ALT≤2.5 times ULN (5 times if liver metastasis occurs)
  • Serum total bilirubin ≤ ULN 1.5 times
  • Serum creatinine <1.5x upper limit (ULN)
  • Urine routine examination, urine protein <2+
  • The internationally standardized ratio (INR)≤1.5 or prothrombin time ULN 1.5 times
  • The activated partial thromboplastin time (aPTT)≤1.5 times ULN time
  • Serum albumin ≥30 g/L
  • Life expectancy ≥3 months;
  • Pregnant women must agree to effective contraception ≥120 days during the study period and after the last drug administration, and the results of serum pregnancy tests were negative 7 days ≤ before the first drug administration;

Who cannot join

  • Patients whose bilateral hydronephrosis can not be alleviated by ureteral stent or percutaneous drainage; non-communicable cystitis CTCAE(5.0 Edition)≥ grade 2;
  • Exclusion criteria of bevacizumab, i.e. clinical significance of cardiovascular and cerebrovascular diseases, abdominal fistula or gastrointestinal perforation history, acute intestinal obstruction or subimpedance, active bleeding;
  • hypertension (systolic blood pressure greater than 140 mmHg and/or diastolic blood pressure greater than 90 mmHg), hypertension crisis or history of hypertensive encephalopathy, which remains uncontrolled under medication;
  • Previous medical history showing newly discovered thrombotic disease within 6 months of screening or during screening; patients with severe wound nonunion, ulcers or fractures;
  • Patients with other malignancies and brain metastases;
  • Patients with central nervous system diseases, including uncontrolled seizure standard drug therapy, or historical cerebrovascular accidents (CVA, stroke), transient ischemic attacks (TIA) or subarachnoid hemorrhage within six months.
Show all 20Show fewer
  • Previous treatment with antiprogrammed cell death protein-1(anti PD-1), antiprogrammed death ligand-1(anti PD-L1) or anti PD-L2 drugs, or have received another drug treatment (e.g., cytotoxic T lymphocyte-associated antigen-4[ CTLA-4]、OX-40,] antigen patients CD137[ tumor necrosis factor receptor superfamily member 9(TNFRSF9)]; A patient who has previously received any VEGF drugs, including bevacizumab.
  • Patients who received live vaccinations or had undergone major surgery within 30 days prior to the first administration of the study; patients who were expected to undergo invasive surgery during treatment;
  • Active autoimmune diseases requiring systemic treatment in the past two years;
  • ≤14 days before the first administration of the study drug, any condition requiring systemic treatment with corticosteroids (prednisone or equivalent >10 mg/ days) or other immunosuppressive drugs;
  • History of known human immunodeficiency virus (HIV) infection;
  • Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers (HBV DNA >500 IU/mL) or active HCV carriers with detectable levels; Note: Non-active hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B patients (HBV DNA <500 IU/mL) can be enrolled;
  • History of interstitial lung disease, non-infectious pneumonia or uncontrolled disease, including pulmonary fibrosis, acute lung disease, etc;
  • Severe chronic or active infections (including tuberculosis infections) requiring systemic antimicrobial, antifungal or antiviral therapy within 14 days prior to the first administration of the study drug Note: Patients with viral hepatitis are allowed antiviral therapy;
  • with severe cardiovascular diseases such as myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass transplantation in the past 6 months, or new york heart disease association (NYHA) class ii-class IV congestive heart failure (CHF), or history of class NYHA III or IV CHF;
  • who are known to be allergic to components of a study drug or its analog;
  • Participate in another clinical study at the same time, unless it is an observational (non-intervention) clinical study or at a follow-up period of an intervention study;
  • Pregnant or lactating women;
  • Previous heterogenous stem cell transplantation or organ transplantation;
  • Other conditions judged by the researchers did not meet the requirements of the group.

Trial locations and contacts

1 site in 1 country.

jianqing zhu, docter contact

13605818467

zjq-hz@126.com

China1 site, 1 recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang

    jianqing zhu, doctor, 13605818467, zjq-hz@126.com

    Recruiting

Other trials in China

About this study

Efficacy and safety of Tislelizumab combined with Bevacizumab and chemotherapy in patients with persistent, recurrent or metastatic cervical cancer.

Read the detailed description

The current standard treatment for persistent, metastatic and recurrent cervical cancer is platinum-based combination chemotherapy as its first-line treatment option. However, the current treatment plan still can not meet the clinical needs of cervical cancer treatment, most patients will progress about 6 months after first-line treatment.

At present, there are many clinical research evidence to support the PD-1 antibody for the treatment of recurrent cervical cancer. Immunotherapy can restore the environment of immune support and promote vascular normalization, while anti-angiogenesis can not only normalize tumor vessels, but also block immunosuppressive signals through many ways, so the two mechanisms complement each other. Inhibition of these two pathways will bring better and more lasting clinical benefits to cervical cancer patients.

This study explores the efficacy and safety of tirelizumab combined with bevacizumab and chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer. combining with immune checkpoint inhibitors on the basis of standard treatment regimens has a more potent and durable antitumor ability mechanistically, no significant adverse reactions overlap between immunotherapy and existing standard regimens from a safety perspective, and multiple immune checkpoint combined with antiangiogenic studies confirm safety in cervical cancer.

Conditions
Cervical Cancer
Being tested
Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
Medical subject headings
Uterine Cervical Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/CarboplatinDrug

    Tisleliumab 200mg, Bevacizumab 7.5mg/kg, Paclitaxel 175mg/m2, and Cisplatin 50mg/m2 (or Carboplatin AUC5) IV on day 1 of every 21-day cycle.

Study groups in NCT05247619
Study groupRoleWhat they receive
InterventionExperimentalTislelizumab + Bevacizumab + Paclitaxel + Cisplatin/Carboplatin
Receives: Drug: Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. mPFS

    mPFS of Tislelizumab in combination with bevacizumab and chemotherapy in patients with persistent, relapsed, or metastatic cervical cancer was assessed by investigators according to RECIST v1.1

    Measured: The time from the first dosing of the study drug until the first objective recording of disease progression or death from any cause, whichever occurred first, up to approximately 24 months.

Secondary outcomes (6)

  1. ORR

    ORR of Tislelizumab in combination with bevacizumab and chemotherapy in patients with persistent, relapsed, or metastatic cervical cancer were assessed by investigators according to RECIST v 1.1

    Measured: Up to approximately 24 months

  2. DCR

    DCR of Tislelizumab in combination with bevacizumab and chemotherapy in patients with persistent, relapsed, or metastatic cervical cancer was assessed by investigators according to RECIST v1.1

    Measured: Up to approximately 24 months

  3. DOR

    DOR of Tislelizumab in combination with bevacizumab and chemotherapy in patients with persistent, relapsed, or metastatic cervical cancer were assessed by investigators according to RECIST v 1.1

    Measured: DOR: refers to the time from the beginning of the first assessment of a tumor as CR or PR to the first assessment of PD or death from any cause, up to 24 months.

  4. Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be presented.

    Measured: The time from the first dosing of the study drug until 90 days after last dose of study treatment (Up to approximately 27 months )

  5. Serious AE (SAE)

    An SAE is defined as any untoward medical occurrence that, at any dose: a.) Results in death; b.) Is life-threatening; c.) Requires inpatient hospitalization or prolongation of existing hospitalization; d.) Results in persistent or significant disability/incapacity; e.) Is a congenital anomaly/birth defect; f.) Other important medical events; h.) Is a new cancer (that is not a condition of the study) or i.) Is associated with an overdose. The number of participants who experience an SAE will be presented.

    Measured: The time from the first dosing of the study drug until 90 days after last dose of study treatment (Up to approximately 27 months )

  6. Immune-related AE (irAE)

    AEs associated with tislelizumab exposure may be a result of an immune response. These irAEs may occur shortly after the first dose or several months after the last dose of tislelizumab treatment .

    Measured: The time from the first dosing of the study drug until 90 days after last dose of study treatment (Up to approximately 27 months )

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2022
  2. Study start30 Jun 2022
  3. Primary completionAug 2024 (estimated)
  4. Study completionJan 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
49 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05247619
Sponsor's protocol ID
BGB-A317-2007
Status last verified
Jul 2022
First submitted
24 Jan 2022
Last updated
15 Jul 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin in people with Cervical Cancer, run by Zhejiang Cancer Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 20 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact jianqing zhu, docter (13605818467, zjq-hz@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

mPFS (time frame: The time from the first dosing of the study drug until the first objective recording of disease progression or death from any cause, whichever occurred first, up to approximately 24 months.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05247619.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in